About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Amiodarone-induced Fatal Acute Liver Injury in COVID-19
Kashif Bin Naeem, Mahmoud Hamouri, Khalid Abdelhameed, Manal Alsakkaf, Alaa Abuquta, Alaa Abdallah, Omar Eltayeb 
Department of Internal Medicine and Cardiology, Al Kuwait Hospital, Dubai, UAE.
Corresponding Author:
Dr Kashif Bin Naeem
Email: kbncardiology@yahoo.co.uk
Received: 25-JAN-2021 Accepted: 15-FEB-2021 Published Online: 20-MAR-2021
DOI: http://dx.doi.org/10.17659/01.2021.0016
Background: Amiodarone is a commonly used anti-arrhythmic drug. Acute liver damage after intravenous administration is rare but can be associated with dramatic rise in hepatic transaminases. We describe a patient with laboratory-confirmed COVID-19 disease who developed fatal acute liver damage with multiorgan dysfunction following intravenous amiodarone. Case Report: A 63-year-old diabetic male was admitted with symptomatic COVID-19 disease. He was stable upon admission. However, his condition worsened and needed respiratory support in intensive care. As a likely consequence of his illness, he developed atrial fibrillation with fast ventricular rate. He was given intravenous amiodarone (300 mg loading dose followed by 900 mg over 24 hours). This was associated with a sudden and dramatic rise in serum transaminases. The amiodarone infusion was stopped and he was given intravenous N-acetylcysteine. However, he developed multiorgan dysfunction and succumbed to the illness. Conclusion: Acute hepatic injury is a rare, potentially fatal, adverse effect of intravenous amiodarone. Physicians need to carefully monitor hepatic function during the amiodarone infusion.
Keywords : Acetylcysteine, Amiodarone, COVID-19, Critical Care, Liver Function Tests.
Article Options
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share